Encouraging efficacy of a comprehensive therapy consisting of sintilimab, bevacizumab biosimilar IBI305, hypo-fractionated intensity-modulated radiotherapy, and oxaliplatin for a maxillary metastasis from hepatocellular carcinoma: A case report and literature review
Oro-maxillo-facial metastasis from hepatocellular carcinoma (HCC) is very rare, and reports on treating maxillary metastasis from HCC are unavailable. Anti-angiogenesis therapy combined with immunotherapy represented by programmed cell death 1 (PD-1) or its ligand (PD-L1) inhibitor has become the st...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-11-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.941454/full |
| _version_ | 1811317361465098240 |
|---|---|
| author | Xuexia Liang Xuexia Liang Qiaodan Liu Wei Yao Shuqin Zhu |
| author_facet | Xuexia Liang Xuexia Liang Qiaodan Liu Wei Yao Shuqin Zhu |
| author_sort | Xuexia Liang |
| collection | DOAJ |
| description | Oro-maxillo-facial metastasis from hepatocellular carcinoma (HCC) is very rare, and reports on treating maxillary metastasis from HCC are unavailable. Anti-angiogenesis therapy combined with immunotherapy represented by programmed cell death 1 (PD-1) or its ligand (PD-L1) inhibitor has become the standard treatment of advanced HCC. However, integrating chemoradiotherapy into immunotherapy–bevacizumab combination therapy has not been reported. Here, we presented a Chinese woman with maxillary metastasis from HCC who achieved a nearly complete response (CR) to a quadruple treatment scheme consisting of a PD-1 monoclonal antibody (sintilimab), bevacizumab biosimilar IBI305, hypo-fractionated intensity-modulated radiotherapy (hfIMRT), and concurrent oxaliplatin. This comprehensive treatment is an innovative and effective therapy for advanced HCC. |
| first_indexed | 2024-04-13T12:05:36Z |
| format | Article |
| id | doaj.art-fdbc47f9f3d7400ea116a40b2ea4e558 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-13T12:05:36Z |
| publishDate | 2022-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-fdbc47f9f3d7400ea116a40b2ea4e5582022-12-22T02:47:39ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-11-011210.3389/fonc.2022.941454941454Encouraging efficacy of a comprehensive therapy consisting of sintilimab, bevacizumab biosimilar IBI305, hypo-fractionated intensity-modulated radiotherapy, and oxaliplatin for a maxillary metastasis from hepatocellular carcinoma: A case report and literature reviewXuexia Liang0Xuexia Liang1Qiaodan Liu2Wei Yao3Shuqin Zhu4Department of Cancer Center, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, ChinaGuangdong Provincial Key Laboratory of Biomedical Imaging, Guangdong Provincial Engineering Research Center of Molecular Imaging, the Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, ChinaDepartment of Cancer Center, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, ChinaDepartment of Cancer Center, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, ChinaDepartment of Pathology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, ChinaOro-maxillo-facial metastasis from hepatocellular carcinoma (HCC) is very rare, and reports on treating maxillary metastasis from HCC are unavailable. Anti-angiogenesis therapy combined with immunotherapy represented by programmed cell death 1 (PD-1) or its ligand (PD-L1) inhibitor has become the standard treatment of advanced HCC. However, integrating chemoradiotherapy into immunotherapy–bevacizumab combination therapy has not been reported. Here, we presented a Chinese woman with maxillary metastasis from HCC who achieved a nearly complete response (CR) to a quadruple treatment scheme consisting of a PD-1 monoclonal antibody (sintilimab), bevacizumab biosimilar IBI305, hypo-fractionated intensity-modulated radiotherapy (hfIMRT), and concurrent oxaliplatin. This comprehensive treatment is an innovative and effective therapy for advanced HCC.https://www.frontiersin.org/articles/10.3389/fonc.2022.941454/fullhepatocellular carcinomamaxillary metastasisPD-1 inhibitorbevacizumabchemoradiotherapy |
| spellingShingle | Xuexia Liang Xuexia Liang Qiaodan Liu Wei Yao Shuqin Zhu Encouraging efficacy of a comprehensive therapy consisting of sintilimab, bevacizumab biosimilar IBI305, hypo-fractionated intensity-modulated radiotherapy, and oxaliplatin for a maxillary metastasis from hepatocellular carcinoma: A case report and literature review Frontiers in Oncology hepatocellular carcinoma maxillary metastasis PD-1 inhibitor bevacizumab chemoradiotherapy |
| title | Encouraging efficacy of a comprehensive therapy consisting of sintilimab, bevacizumab biosimilar IBI305, hypo-fractionated intensity-modulated radiotherapy, and oxaliplatin for a maxillary metastasis from hepatocellular carcinoma: A case report and literature review |
| title_full | Encouraging efficacy of a comprehensive therapy consisting of sintilimab, bevacizumab biosimilar IBI305, hypo-fractionated intensity-modulated radiotherapy, and oxaliplatin for a maxillary metastasis from hepatocellular carcinoma: A case report and literature review |
| title_fullStr | Encouraging efficacy of a comprehensive therapy consisting of sintilimab, bevacizumab biosimilar IBI305, hypo-fractionated intensity-modulated radiotherapy, and oxaliplatin for a maxillary metastasis from hepatocellular carcinoma: A case report and literature review |
| title_full_unstemmed | Encouraging efficacy of a comprehensive therapy consisting of sintilimab, bevacizumab biosimilar IBI305, hypo-fractionated intensity-modulated radiotherapy, and oxaliplatin for a maxillary metastasis from hepatocellular carcinoma: A case report and literature review |
| title_short | Encouraging efficacy of a comprehensive therapy consisting of sintilimab, bevacizumab biosimilar IBI305, hypo-fractionated intensity-modulated radiotherapy, and oxaliplatin for a maxillary metastasis from hepatocellular carcinoma: A case report and literature review |
| title_sort | encouraging efficacy of a comprehensive therapy consisting of sintilimab bevacizumab biosimilar ibi305 hypo fractionated intensity modulated radiotherapy and oxaliplatin for a maxillary metastasis from hepatocellular carcinoma a case report and literature review |
| topic | hepatocellular carcinoma maxillary metastasis PD-1 inhibitor bevacizumab chemoradiotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.941454/full |
| work_keys_str_mv | AT xuexialiang encouragingefficacyofacomprehensivetherapyconsistingofsintilimabbevacizumabbiosimilaribi305hypofractionatedintensitymodulatedradiotherapyandoxaliplatinforamaxillarymetastasisfromhepatocellularcarcinomaacasereportandliteraturereview AT xuexialiang encouragingefficacyofacomprehensivetherapyconsistingofsintilimabbevacizumabbiosimilaribi305hypofractionatedintensitymodulatedradiotherapyandoxaliplatinforamaxillarymetastasisfromhepatocellularcarcinomaacasereportandliteraturereview AT qiaodanliu encouragingefficacyofacomprehensivetherapyconsistingofsintilimabbevacizumabbiosimilaribi305hypofractionatedintensitymodulatedradiotherapyandoxaliplatinforamaxillarymetastasisfromhepatocellularcarcinomaacasereportandliteraturereview AT weiyao encouragingefficacyofacomprehensivetherapyconsistingofsintilimabbevacizumabbiosimilaribi305hypofractionatedintensitymodulatedradiotherapyandoxaliplatinforamaxillarymetastasisfromhepatocellularcarcinomaacasereportandliteraturereview AT shuqinzhu encouragingefficacyofacomprehensivetherapyconsistingofsintilimabbevacizumabbiosimilaribi305hypofractionatedintensitymodulatedradiotherapyandoxaliplatinforamaxillarymetastasisfromhepatocellularcarcinomaacasereportandliteraturereview |